SymBio Pharmaceuticals Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-4,748	-3,806	-1,195	2,106	2,032
Depreciation & Amortization	-	-	98	99	93.96
Other Amortization	-	-	-	-	1.95
Loss (Gain) From Sale of Assets	109	131	568	-	0.69
Stock-Based Compensation	-	-	-	-	124.27
Other Operating Activities	2	27	-377	-420	-1,048
Change in Accounts Receivable	163	489	1,171	62	-1,741
Change in Inventory	-50	54	237	-82	559.24
Change in Accounts Payable	-169	-215	-356	662	-595.78
Change in Other Net Operating Assets	118	-96	-340	-813	711.88
Operating Cash Flow	-4,575	-3,416	-194	1,614	140.04
Operating Cash Flow Growth	-	-	-	1052.51%	-
Capital Expenditures	-	-19	-204	-2	-25.45
Sale (Purchase) of Intangibles	-82	-27	-28	-45	-38.38
Other Investing Activities	7	43	-144	-	-7.01
Investing Cash Flow	-75	-3	-376	-47	-70.85
Long-Term Debt Issued	2,924	-	-	-	-
Long-Term Debt Repaid	-552	-	-	-	-
Net Debt Issued (Repaid)	2,372	-	-	-	-
Issuance of Common Stock	1,249	709	681	630	0.9
Repurchase of Common Stock	-	-	-	-2	-68.83
Other Financing Activities	-	-1	-1	-1	-4
Financing Cash Flow	3,621	708	680	627	-71.92
Foreign Exchange Rate Adjustments	-50	158	125	213	14.21
Miscellaneous Cash Flow Adjustments	-1	-	-1	14	-
Net Cash Flow	-1,080	-2,553	234	2,421	11.48
Free Cash Flow	-4,575	-3,435	-398	1,612	114.59
Free Cash Flow Growth	-	-	-	1306.78%	-
Free Cash Flow Margin	-350.04%	-140.09%	-7.12%	16.11%	1.39%
Free Cash Flow Per Share	-91.11	-76.17	-9.97	40.70	2.95
Cash Interest Paid	39	-	-	-	-
Cash Income Tax Paid	12	-39	354	363	3.8
Levered Free Cash Flow	-3,089	-2,055	-143.5	1,542	-226.95
Unlevered Free Cash Flow	-2,996	-2,055	-143.5	1,542	-226.95
Change in Working Capital	62	232	712	-171	-1,065